Shashank R. Pinnapireddy
Has grant
Head of Nanoparticle Research
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Shashank R. Pinnapireddy serves as the Head of Nanoparticle Research at CSL Behring in Germany. His research focuses on innovative drug delivery systems, including the application of lipopolyplexes and nanoparticles in cancer therapy and anti-inflammatory treatments. Recent publications highlight his work on photoselective gene transfection and bioactive compounds for targeted therapies. He continues to advance the field through the exploration of various nanocarrier technologies and their efficacy in medical applications.
Recent Grants
Grant: Close
siRNA Therapy of HPV induced head and neck carcinomas
Open Date: 2019-04-01
Close Date: 2019-04-01
Grant: Close
Composite nanocarriers for gene delivery
Open Date: 2018-09-01
Close Date: 2018-09-01
Grant: Close
Radio-Gene Therapy of head and neck carcinomas
Open Date: 2018-04-01
Close Date: 2018-04-01
Articles (10)
Year:
2024
The cottontail rabbit papillomavirus (CRPV)-associated VX2 carcinoma of the New Zealand White rabbit serves as a model system for human papillomavirus (HPV)-associated head and neck squamous cell carcinomas (HNSCCs). The aim of this study was to evaluate the tumor-inhibiting effect of RNAi-mediated knockdown of the CRPV oncogenes, E6 and E7, using siRNA-loaded lipopolyplexes (LPPs). VX2-carcinoma-derived cells were cultured for up to 150 passages. In addition, CRPV E6 and E7 oncogenes were transiently expressed in COS-7 cells. Efficiency and safety of LPPs were evaluated in both VX2 cells and the COS-7 cell line. Both of these in vitro CRPV systems were validated and characterized by fluorescence microscopy, Western blot, and RT-qPCR. Efficient knockdown of CRPV E6 and E7 was achieved in VX2 cells and COS-7 cells pretransfected with CRPV E6 and E7 expression vectors. Knockdown of CRPV oncogenes in VX2 cells resulted in reduced viability, migration, and proliferation and led to a G0/G1 block in the cell cycle. CRPV E6 and E7 siRNA-loaded LPPs could represent promising therapeutic agents serving as a paradigm for the treatment of papillomavirus-positive cancers and could be of value for the treatment of CRPV-associated diseases in the rabbit such as papillomas and cancers of the skin.
Year:
2023
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Collaborators (7)
Robert Mandic
University Hospital Marburg
Michaela Schulz-Siegmund
Professorin, W3
Leipzig University
Christian Wölk
-
Richard Harvey
Universität Wien
Michael Bette
Associated Professor
Philipps-Universität Marburg
Manfred Ogris
Universität Wien
Udo Bakowsky
University of Marburg
Make your next move.
Prepare your application
Review drafts before you send them.